ImmunoGen, Inc. Announces Presentations at Upcoming AACR Annual Meeting 2015
"The presentations on ADCs by ImmunoGen researchers and our partners at
AACR this year illustrate our ongoing commitment to advancing the ADC
field to achieve better therapies for people with cancer," commented
Presentations Related to ImmunoGen, Partner ADCs
- "Development and application of an immunohistochemistry-based clinical assay for evaluating Folate Receptor Alpha (FRα) expression in a phase I clinical trial of IMGN853." Abstract number: 4357
- "Plasma pharmacokinetics and tumor accumulation in mice of IMGN779, an antibody-drug conjugate for acute myeloid leukemia." Abstract number: 4504
- "In vitro and in vivo activity of a highly potent and novel FGFR2/FGFR4 dual targeting antibody-drug conjugate." Abstract number:1680
- "Development and activity of a novel antibody-drug conjugate for the treatment of P-cadherin expressing cancers." Abstract number: 1682
- "A novel anti-CEACAM5 maytansinoid-antibody-drug conjugate for the treatment of colorectal, lung and gastric tumors." Abstract number: 1688
- "Generation of a novel maytansinoid-antibody-drug conjugate targeting LAMP1 expressed on the surface of tumor cells." Abstract number: 1689
- "Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML." Abstract number: 1695
- "A c-Kit targeting antibody-drug conjugate is efficiently metabolized and activated inside cancer cell lines and xenograft tumors." Abstract number: 5325
Presentations by ImmunoGen Scientists on ADC Technology Innovations
Site-specific linkage; payload molecules/antibody - benefit assessment, novel approaches
- "Stability and efficacy comparison of site-specific and lysine-linked maytansinoid antibody-drug conjugates." Abstract number: 645
- "SeriMabs: N-terminal serine modification enables modular, site-specific payload incorporation into antibody-drug conjugates (ADCs)." Abstract number: 647
- "Antibody-drug conjugates: engineered N-terminal serine residues as a novel approach for site-specific conjugation." Abstract number: 653
- "Effects of drug load on therapeutic index for antibody-maytansinoid conjugates." Abstract number: 4531
Expanding portfolio of novel payload agents
- "Antibody-drug conjugates (ADCs) of indolino-benzodiazepine DNA-alkylating agents." Abstract number: 652
Advancing ADC screening methodologies
- "Microscale methods for preparation and screening of antibody-drug conjugates." Abstract number: 5442
Additional information - including abstracts and presentation schedule - can be found at www.aacr.org
About
Kadcyla® is a registered trademark of
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including risks related to preclinical and clinical studies, their
timings and results. A review of these risks can be found in ImmunoGen's
Annual Report on Form 10-K for the fiscal year ended
For Investors:
info@immunogen.com
or
For
Media:
Source:
News Provided by Acquire Media